Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cormedix ( (CRMD) ) just unveiled an announcement.
On April 27, 2026, CorMedix announced positive topline data from the global Phase III ReSPECT trial of REZZAYO (rezafungin) in adult patients undergoing allogeneic hematopoietic stem cell transplantation, a group at high risk of invasive fungal diseases. The once‑weekly rezafungin regimen achieved non‑inferior Day 90 fungal‑free survival versus a standard antimicrobial regimen, with 60.7% fungal‑free survival compared with 59.0% on standard therapy.
The study showed comparable efficacy and mortality between treatment arms against Candida, Aspergillus and Pneumocystis, but highlighted a favorable safety and tolerability profile for rezafungin, including fewer toxicity‑related discontinuations and fewer treatment‑emergent adverse events leading to dose modification or study withdrawal. Sponsored by Mundipharma, which holds ex‑U.S. rights, the trial outcome strengthens REZZAYO’s positioning as a potential prophylactic option in immunocompromised transplant patients and supports CorMedix’s efforts to broaden the drug’s label in a large U.S. hospital market for invasive fungal prophylaxis.
The most recent analyst rating on (CRMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
The score is driven primarily by sharply improved 2025 financial performance and cash generation, tempered by sustainability concerns. Technicals materially detract due to a clear downtrend and weak momentum signals. Valuation is supportive via a low P/E, while earnings-call guidance and catalysts are balanced by significant reimbursement-driven pricing and concentration risks.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Therapeutics, listed on Nasdaq as CRMD, is a U.S. biopharmaceutical company focused on developing and commercializing treatments for life‑threatening conditions. The company markets its products primarily to hospitals, clinics and infusion centers, and currently sells rezafungin (REZZAYO) for the treatment of candidemia and invasive candidiasis in adults.
CorMedix operates with a field‑based medical and commercial infrastructure deployed across institutional care settings in the U.S. Its strategy centers on high‑risk, immunocompromised patient populations where invasive fungal infections remain a significant unmet medical need, and where differentiated dosing and safety profiles can support adoption of new antifungal therapies.
Average Trading Volume: 1,479,968
Technical Sentiment Signal: Sell
Current Market Cap: $581.9M
For an in-depth examination of CRMD stock, go to TipRanks’ Overview page.